MP 4F10 may be used in clinical studies for tumour grading as it will stain both moderately and well-differentiated colorectal adenocarcinoma.
| Inventor | Institute |
|---|---|
| Walter Bodmer | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151134 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Developmental biology;Stem cell biology |
| Application: | IF ; ICC ; FACS ; IHC ; IP ; WB |
| Target: | Integrin alpha6 (CD49f) |
| Reactivity: | Human |
| Clone: | MP4F10 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Pignatelli et al. 1990. Proc Natl Acad Sci U S A. 87(4):1541-5. PMID: 2304917. |
| Product description: | MP 4F10 may be used in clinical studies for tumour grading as it will stain both moderately and well-differentiated colorectal adenocarcinoma. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | 118/100 |
| Immunogen: | SW1222 human colorectal cell line. |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha 6 is found on epithelial and endothelial basement membranes and colorectal carcinoma. Integrin alpha 6 associates with integrin beta 4 to form integrin a6b4, one of the most abundant keratinocyte integrins, and binds laminin. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Zhou et al. 2019. Stem Cell Res Ther. 10(1):155. PMID: 31151466. Pieri et al. 2019. Stem Cell Res Ther. 10(1):135. PMID: 31109365. Kapsokalyvas et al. 2017. Colloids Surf B Biointerfaces. 159:97-107. PMID: 28780465. Zhang et al. 2017. PLoS One. 12(2):e0172207. PMID: 28234938. Zhang et al. 2016. Cell Reprogram. 18(6):401-410. PMID: 27906584. Al Thawadi et al. 2016. Oncotarget. 7(5):5289-305. PMID: 26700621. Stempin et al. 2015. Cancer Cell Int. 15:110. PMID: 26612978. Svensson Mnsson et al. 2007. J Pathol. 212(1):102-11. PMID: 17370299. Levy et al. 2000. Mol Biol Cell. 11(2):453-66. PMID: 10679006. Anbazhagan et al. 1995. J Pathol. 176(3):227-32. PMID: 7674085. Pignatelli et al. 1990. Proc Natl Acad Sci U S A. 87(4):1541-5. PMID: 2304917. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.